Physician profile
Amanda E Smith
NPI 1952541203
$1,582.33
in general payments reported to CMS, 2019-2025
26 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.90 · 2020: $59.67 · 2021: $36.74 · 2022: $89.38 · 2023: $389 · 2024: $526 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $564.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $190.46 | 2020-2025 | |
| Exact Sciences Corporation | $89.72 | 2023-2024 | Cologuard Collection Kit |
| Biomerieux INC | $69.51 | 2025 | |
| Astellas Pharma US INC | $55.75 | 2023-2024 | Myrbetriq, Veozah |
| Abbott Laboratories | $50.20 | 2021-2025 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $49.77 | 2025 | Dojolvi |
| Merck Sharp & Dohme LLC | $48.21 | 2020-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Lilly USA, LLC | $47.09 | 2022-2025 | Zepbound, Mounjaro |
| Amneal Pharmaceuticals LLC | $45.70 | 2024 | Unithroid |
| Biohaven Pharmaceutical Holding Company LTD. | $34.90 | 2022 | |
| Abbvie INC. | $33.38 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.32 | 2023-2024 | Xifaxan, Trulance |
| Avanir Pharmaceuticals, INC. | $29.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $29.40 | 2024 | Airsupra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.63 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $24.21 | 2025 | Aptima |
| Phadia US INC. | $22.44 | 2023 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $21.20 | 2021 | |
| Cipher Pharmaceuticals US LLC | $20.62 | 2025 | Natroba, Spinosad |
| Novartis Pharmaceuticals Corporation | $18.47 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.08 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.25 | 2024 | |
| Ironwood Pharmaceuticals, INC | $16.96 | 2024 | |
| Cranial Technologies, INC | $16.24 | 2024 | Doc Band |
| Boston Scientific Corporation | $11.99 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.